1-Deamino-8-D-arginine vasopressin in the treatment of non-haemophilic patients with acquired factor VIII inhibitor.
1-Deamino-8-D-arginine vasopressin (DDAVP) was administered to 3 patients with spontaneous factor VIII inhibitors. In 2 patients with baseline factor VIII levels above 1%, a marked increase of factor VIII activity after DDAVP infusion could be observed. No rise of factor VIII activity after DDAVP was seen in the 3rd patient with a baseline factor VIII level of less than 1%. Daily infusion of DDAVP resulted in a reduction of the efficacy, but the full effect could be retained when DDAVP was given at 48-hour intervals. The effect of DDAVP infusion on factor VIII levels in the 2 responding patients was superior to the treatment with 30 U/kg factor VIII concentrate and approximately equivalent to infusion of 45 U/kg factor VIII concentrate. DDAVP may be a useful and less expensive treatment for patients with acquired factor VIII inhibitors and a baseline factor VIII level of more than 1%.
Muhm
M
M
First Department of Medicine, University of Vienna, Austria.
Grois
N
N
Kier
P
P
Stümpflen
A
A
Kyrle
P
P
Pabinger
I
I
Bettelheim
P
P
Hinterberger
W
W
Lechner
K
K
D000368:Aged; D001778:Blood Coagulation Disorders / Q000097:blood / Q000188:drug therapy*; D002648:Child; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000627:therapeutic use*; D005169:Factor VIII / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D006801:Humans; D008297:Male
D005169:Factor VIII; D003894:Deamino Arginine Vasopressin